Reversing the restrictive trend in diffuse large B‐cell lymphoma trial eligibility: it’s time to open the gates!
Author:
Affiliation:
1. Division of Hematology Mayo Clinic Rochester MNUSA
2. Department of Quantitative Health Sciences Mayo Clinic Rochester MN USA
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17433
Reference18 articles.
1. Fda Cder.Public Workshop: evaluating inclusion and exclusion criteria in clinical trials.2018. Available at:www.fda.gov. (Accessed February 6 2021).
2. National Cancer Institute.Making cancer clinical trials available to more patients. Available at:https://www.cancer.gov/news‐events/cancer‐currents‐blog/2019/expanding‐clinical‐trial‐eligibility‐criteria. (Accessed February 3 2021).
3. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
4. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation
5. Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3